Gerresheimer Logo
DE000A0LD6E6
A0LD6E
GXI.DE

Gerresheimer

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.


  • Gerresheimer: adjusted EBITDA falls 19% – shares rise 2.8% after cash‑flow improvement

    Gerresheimer reports adjusted EBITDA of €66m for Q1 2026 (-19%) and a margin of 12.6% (previous year 15.7%), on slightly higher revenue of €524m. Free cash flow improved significantly to -€32m from -€141m, driven by active inventory reduction and throttled production volumes, which weigh on profitability in the short term. The Containment & Delivery Systems segment performed positively with a higher margin due to strong demand and new U.S. production ramp‑ups. The quarterly release was delayed due to internal reviews of revenue recognition, the company still lacks a permanent CEO, and management is aiming for a turnaround in the second half. » Altro su de.investing.com


  • Gerresheimer rises sharply after improved free cash flow and optimistic H2 forecast

    The Gerresheimer share climbed about 5.7% to €26.68 after the company published preliminary Q1 figures showing a marked improvement in free cash flow. Revenue rose slightly to €524m, but adjusted EBITDA fell from €81m to €66m and the margin dropped to 12.6% due to a strategic realignment in favor of cash generation. Investors were also reassured by a more optimistic expectation for the second half of the year despite the recent CEO change to interim co‑leadership. » Altro su de.investing.com


  • Gerresheimer starts the fiscal year weakly and is counting on the second half

    Gerresheimer reports a slight revenue increase to €524 million for the first quarter, but adjusted EBITDA fell from €81 million to €66 million. The company expects improvements from the already approved sales of Centor and Primary Packaging Plastics, which are only set to take effect in the second half of the year. Management had delayed the quarterly report after BaFin reviews uncovered accounting errors, leading to corrections, leadership changes and a group loss of almost €319 million. The share price rose by just under 5% after the figures, and the recovery in the stock has raised hopes of a return to the SDax. » Altro su finanzen.net

Nel 2025, Gerresheimer ha già distribuito +0,04 di dividendi. L'ultimo pagamento è avvenuto a giugno 2025.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Gerresheimer ha registrato ricavi pari a +639,49M e un utile netto di 306,63M
(EUR) nov 2025
YoY
Ricavi +639,49M -
Utile lordo +1,78M -
Utile netto 306,63M -
EBITDA +35,02M -

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
+886,99M
Numero di azioni
34,54M
Massimo/minimo a 52 settimane
+45,24 - +14,83
Dividendi No
Beta
0,47
Rapporto P/E
2,77
Rapporto PEG
+0,01
Rapporto P/B
+0,82
Rapporto P/S
+0,38

Profilo aziendale

Die Gerresheimer AG produziert und vertreibt zusammen mit ihren Tochtergesellschaften weltweit Verpackungsprodukte sowie Geräte und Lösungen zur Verabreichung von Medikamenten. Das Unternehmen ist in den Geschäftsbereichen Plastics & Devices, Primary Packaging Glass und Advanced Technologies tätig. Der Geschäftsbereich Plastics & Devices bietet Systeme zur Verabreichung von Medikamenten an, darunter Inhalatoren, Insulin-Pen-Systeme, vorfüllbare Spritzen und Diagnosesysteme für die Pharma-, Biotech-, Diagnostik- und Medizintechnikindustrie; Behälter und Verschlüsse, PET-Flaschen, Augentropfer, Nasensprays, Vernebler, Applikatoren und Zubehör für feste, flüssige und ophthalmische Anwendungen sowie Flaschen und Behälter für Nahrungsergänzungsmittel. Der Geschäftsbereich Primary Packaging Glass bietet Primärverpackungen aus Glas für die Pharma- und Kosmetikindustrie an, z. B. Infusions-, Tropfflaschen und Sirupflaschen, Injektionsfläschchen, Ampullen und Karpulen, Miniaturflaschen und Glasbehälter für flüssige Lebensmittel, Gewürze und Spirituosen sowie Verpackungslösungen für Parfüms, Deodorants, Hautpflege- und Wellnessprodukte sowie Beauty- und Pharmaprodukte. Der Geschäftsbereich Advanced Technologies entwickelt für Kunden aus der Pharma- und Biotech-Branche intelligente Verabreichungssysteme für Medikamente, wie z. B. Mikropumpen, die zur Selbstverabreichung von Medikamenten gegen die Parkinson-Krankheit oder Herzinsuffizienz eingesetzt werden. Das Unternehmen wurde 1864 gegründet und hat seinen Hauptsitz in Düsseldorf, Deutschland.

Nome
Gerresheimer
CEO
Uwe Ferdinand Röhrhoff
Sede centrale Düsseldorf, nw
Germania
Sito web
Settore
Sanità
Industria
Tecnologia sanitaria
Quotazione in borsa
11/06/2007
Dipendenti 13.528

Simboli di borsa

Borsa Simbolo
XETRA
GXI.DE
Pnk
GRRMF
SIX
GXI.SW
Frankfurt
GXI.F
Düsseldorf
GXI.DU
Hamburg
GXI.HM
London
0NTI.L
München
GXI.MU
Wien
GXI.VI
🍪

Parqet  usa i cookie. Scopri di più